Open AccessGlucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease
Author(s) -
Минара Шамхаловна Шамхалова,
Шамхалова Минара Шамхаловна,
Ivona Renata Yarek-Martynova,
Ярек-Мартынова Ивона Рената,
Natalya Petrovna Trubitcyna,
Трубицына Наталья Петровна,
Marina Shestakova,
Шестакова Марина Владимировна
Publication year - 2013
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-823
Subject(s) - medicine , diabetes mellitus , kidney disease , dyslipidemia , diabetic nephropathy , disease , population , type 2 diabetes mellitus , endocrinology , nephropathy , intensive care medicine , environmental health
Expansion of diabetic population (predominantly due to type 2 diabetes mellitus) with chronic kidney disease (CKD) comorbidityconstitutes one of the major challenges in modern medicine.Throughout the course of diabetes nephropathy development, from its debut to the terminal stage, survival rate and quality of life arelower than those of other categories of patients. This indicates crucial role of hyperglycemia in accelerated metabolic degradation typicalof CKD.Renal disease severely narrows the spectrum of available glucose-lowering agents. Concurrent treatment for hypertension and dyslipidemia,as well as anti-platelet therapy and stimulation of erythropoiesis becomes a complex issue. A creative and patient-orientedapproach with clear metabolic and cardiovascular goals should be instrumental in its solution.